Literature DB >> 22111969

Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.

Hans E Johnsen, Corrine Haioun, Pieternella J Lugtenburg, Antonio Salar, Ulrich Jaeger, Ruth Pettengell, Francesca G Rossi, Gregor Verhoef, Matthias Schwenkglenks, Kate Bendall, Ulrich Duehrsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22111969     DOI： 10.3109/10428194.2011.643407

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.

Authors:  Umberto Vitolo; Francesco Angrili; Lucy DeCosta; Sally Wetten; Massimo Federico
Journal:  Med Oncol       Date:  2016-11-07       Impact factor: 3.064

2.  Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.

Authors:  Derek Weycker; Aurelie Danel; Anne Marciniak; Kate Bendall; Michael Lipsitz; Ruth Pettengell
Journal:  BMC Cancer       Date:  2012-08-22       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.